Johnson & Johnson JNJ and Pfizer PFE are two of the world’s largest pharmaceutical companies with diversified healthcare ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...

J&J revealed that its proposed prepackaged bankruptcy plan for Red River Talc LLC was not approved by the U.S. Bankruptcy Court for the Southern District of Texas. Instead of appealing, J&J plans to ...

Accessed March 2025. 3 J&J Data on file (RF-433976). European Medicines Agency. Updated TREMFYA Summary of Product Characteristics. Accessed March 2025. 5 EU SmPC: European Medicines Agency. TREMFYA ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...